MS drug risk sharing scheme could not yield valid data after only two years follow up.
As chair of the Scientific Advisory Committee (SAG) of the Multiple Sclerosis Risk Sharing Scheme I strongly reject the suggestion that our advice is based on any considerations other than scientific rigour.
Members of DH and of the 4 companies attend meetings with observer status only. Final decisions relating to the scheme, e.g. on whether to apply price adjustments at any point, are taken between the parties to the scheme informed by advice from my committee. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1893